Enterprise Value
281.3M
Cash
65.05M
Avg Qtr Burn
-22.34M
Short % of Float
5.26%
Insider Ownership
9.97%
Institutional Own.
69.61%
Qtr Updated
03/31/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
JELMYTO® (mitomycin) Details Carcinoma | Approved Quarterly sales | |
Phase 3 Data readout |